|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Department of Epidemiology (A.D.W., B.R.), UCLA School of Public Health; and the Department of Neurology (J.M.B., Y.M.B.), David Geffen School of Medicine at UCLA and the Greater Los Angeles Veterans Administration Medical Center, Los Angeles, CA.
* To whom correspondence should be addressed. E-mail: awahner{at}ucla.edu.
ABSTRACT
Objective: To investigate associations between statin (3-hxydroxy-3-methylglutaryl-coenzyme A reductase inhibitor) use and Parkinson disease (PD).
Methods: We used a population-based design to recruit 312 incident idiopathic PD cases and 342 controls from three rural California counties.
Results: We observed a higher frequency of statin use among controls vs cases (OR 0.45; 95% CI 0.29 to 0.71) and a strong dose-response relation. The strongest protective association between statin use and PD was observed in long-term (
5 years) users (OR 0.37; 95% CI 0.18 to 0.78). There was no difference by gender or age. We noted 60 to 70% risk reductions for each individual statin except pravastatin.
Conclusion: Ascribing causality to these associations is premature and further studies are needed to confirm a potential neuroprotective role for statins in PD.
This article has been cited by other articles:
![]() |
A. Ghosh, A. Roy, J. Matras, S. Brahmachari, H. E. Gendelman, and K. Pahan Simvastatin Inhibits the Activation of p21ras and Prevents the Loss of Dopaminergic Neurons in a Mouse Model of Parkinson's Disease J. Neurosci., October 28, 2009; 29(43): 13543 - 13556. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |